XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.22.1

BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES (Tables) | 6 Months Ended
--- | ---
Mar. 31, 2022
BASIS OF PRESENTATION AND SUMMARY OF ACCOUNTING POLICIES |
Schedule of operations and timing of revenue recognition | The following table presents revenues disaggregated by our business operations and timing of revenue recognition: ​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | Three Month Period Ended:
​ | ​ | March 31, | ​ | March 31,
​ |  | 2022 |  | 2021
Research and development services (over-time) | ​ | $ | 219,898 | ​ | $ | 124,760
Clinical laboratory testing services (point-in-time) | ​ | ​ | 4,331,867 | ​ | ​ | 1,425,980
Clinical laboratory testing services (over-time) | ​ | ​ | 1,158,375 | ​ | ​ | 128,900
Product and authentication services (point-in-time): | ​ |  | ​ | ​ |  | ​
Supply chain | ​ |  | 115,463 | ​ |  | 67,057
Asset marking | ​ |  | 141,657 | ​ |  | 140,169
Diagnostic test kits | ​ | ​ | 180,023 | ​ | ​ | 784,676
Total | ​ | $ | 6,147,283 | ​ | $ | 2,671,542
​
​ | ​ | ​ | ​ | ​ | ​ | ​
​ |  | Six Month Period Ended:
​ | ​ | March 31, | ​ | March 31,
​ |  | 2022 |  | 2021
Research and development services (over-time) | ​ | $ | 325,591 | ​ | $ | 388,473
Clinical laboratory testing services (point-in-time) | ​ |  | 6,205,589 | ​ |  | 2,003,250
Clinical laboratory testing services (over-time) | ​ |  | 2,484,775 | ​ |  | 324,400
Product and authentication services (point-in-time): | ​ |  | ​ | ​ |  | ​
Supply chain | ​ |  | 527,295 | ​ |  | 99,999
Asset marking | ​ |  | 246,895 | ​ |  | 291,927
Diagnostic test kits | ​ |  | 522,844 | ​ |  | 1,179,634
Total | ​ | $ | 10,312,989 | ​ | $ | 4,287,683
Schedule of opening and closing contract balances | The opening and closing balances of the Company’s contract balances are as follows: ​
​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​ | ​
​ | ​ | ​ | ​ | October 1, | ​ | March 31, | ​ | $
​ |  | Balance sheet classification |  | 2021 |  | 2022 |  | change
Contract liabilities |  | Deferred revenue | ​ | $ | 281,000 | ​ | $ | 393,656 | ​ | $ | 112,656
​
Schedule of anti-dilutive securities not included computation of net loss per share | ​
​ | ​ | ​ | ​ | ​
​ |  | 2022 |  | 2021
Warrants |  | 2,239,963 |  | 776,518
Stock options |  | 1,067,614 |  | 408,085
Total |  | 3,307,577 |  | 1,184,603

X
- References No definition available. + Details
Name: | us-gaap_AccountingPoliciesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045 + Details
Name: | us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -URI http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257 + Details
Name: | us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration